Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease.
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes complicated by non-alcoholic fatty liver disease
- Registration Number
- JPRN-UMIN000018166
- Lead Sponsor
- Toranomon Hospital, Department of Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Contraindication for SGLT2 inhibitor. Ineligible patients by judgement of family doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Histologial changes of liver and safety of treament are evaluated at two points of the baseline and 24 weeks after the start of treatment.
- Secondary Outcome Measures
Name Time Method Fasting plasma glucose, hemoglobin A1c, aspartate aminotransferase, alanine aminotransferase, and body composition are evaluated at two points of the baseline and 24 weeks after the start of treatment.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link SGLT2 inhibition to NAFLD improvement in type 2 diabetes patients?
How do SGLT2 inhibitors compare to GLP-1 receptor agonists in managing diabetes-related NAFLD?
Which biomarkers correlate with SGLT2 inhibitor efficacy in NAFLD-complicated type 2 diabetes?
What adverse events are associated with SGLT2 inhibitor use in NAFLD patients with diabetes?
Are there combination therapies involving SGLT2 inhibitors that enhance NAFLD outcomes in diabetic individuals?